Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arzneiwerk AG VIDAHAM:TLIK 40 Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus rates HAM:TLIK with a GF Score™ of 40/100. The stock has 7 warning signs investors should review. Among 91 Medical Distribution companies, Arzneiwerk AG VIDA ranks worse than 1098900% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Arzneiwerk AG VIDA's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of Arzneiwerk AG VIDA was 8.86. The lowest was -0.07. And the median was 1.25.
HAM:TLIK's Debt-to-EBITDA is not ranked *
in the Medical Distribution industry.
Industry Median: 2.31 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Arzneiwerk AG VIDA Debt-to-EBITDA Related Terms
Arzneiwerk AG VIDA Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Arzneiwerk AG VIDA's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:TLIK vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Arzneiwerk AG VIDA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arzneiwerk AG VIDA Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arzneiwerk AG VIDA's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Arzneiwerk AG VIDA's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Arzneiwerk AG VIDA (HAM:TLIK) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Arzneiwerk AG VIDA. According to the industry distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 91 companies in the Medical Distribution industry.
Is Arzneiwerk AG VIDA's Debt-to-EBITDA too high?
Arzneiwerk AG VIDA's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 91 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Arzneiwerk AG VIDA has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Arzneiwerk AG VIDA's Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arzneiwerk AG VIDA ranks #999999 out of 91 companies for Debt-to-EBITDA. This places Arzneiwerk AG VIDA in the lower half of its industry. The industry median Debt-to-EBITDA is 2.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.31, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Arzneiwerk AG VIDA. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arzneiwerk AG VIDA's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arzneiwerk AG VIDA stock overvalued right now?
Arzneiwerk AG VIDA (HAM:TLIK) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Arzneiwerk AG VIDA's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Arzneiwerk AG VIDA (HAM:TLIK), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe.
40GF Score
Get the complete analysis for HAM:TLIK
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:TLIK has been successfully added to your 
